Dalteparina Dosing in Renal Insufficiency

Introduction to Dalteparina Dosing

The American College of Cardiology recommends that dalteparina does not require dose adjustment for prophylaxis (5000 IU daily) in severe renal insufficiency, but monitoring of anti-Xa levels is required for therapeutic doses when creatinine clearance is <30 mL/min 1
The American Society of Hematology suggests that no dose adjustment is required for dalteparina prophylaxis (5000 IU daily) in severe renal insufficiency (ClCr <30 mL/min), as there is no significant bioaccumulation with prophylactic doses 1

The European Society of Cardiology states that in patients with ClCr <30 mL/min receiving therapeutic doses, monitoring of anti-Xa levels is mandatory to determine the appropriate dose 3
The International Society on Thrombosis and Haemostasis recommends a target range of 0.5-1.5 IU/mL for anti-Xa levels, with sampling 4-6 hours after administration, and frequency after 3-4 doses administered 1, 3

The American Heart Association notes that enoxaparina requires mandatory dose reduction in ClCr <30 mL/min, with a higher risk of bleeding with standard doses in severe renal insufficiency (8.3% vs 2.4%) 2
The European Renal Association advises that tinzaparina should be completely avoided in patients ≥70 years with renal insufficiency due to increased mortality observed in clinical trials 1, 2, 5

For patients with renal insufficiency who require anticoagulation, the National Kidney Foundation recommends calculating creatinine clearance, and if ClCr ≥30 mL/min, using dalteparina at standard dose (prophylaxis or therapeutic) without adjustment, with no routine monitoring of anti-Xa levels 1, 2
If ClCr <30 mL/min, the American College of Clinical Pharmacy suggests using dalteparina for prophylaxis at 5000 IU daily without adjustment, and for treatment with mandatory monitoring of anti-Xa levels 1, 3

The Journal of Clinical Oncology reports that in the CLOT trial, patients with cancer and renal insufficiency (ClCr <60 mL/min) treated with dalteparina had 2.7% recurrence of venous thromboembolism vs 17% with vitamin K antagonists (P=0.01), with no significant difference in bleeding rates between treatment groups 3, 4
Only 1 of 74 patients with renal insufficiency required dose reduction due to elevated anti-Xa levels 3, 4